SEC EDGARAUG 62 min read$ILMN

Meister Keith A. sold $148.2M of ILMN (indirect holdings)

Meister Keith A. sold 741,127 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $199.91 ($196.74–$203.28, $148.16M total) across 14 trades over 2026-08-04 to 2026-08-05.

Original reporting

SEC EDGAR · Meister Keith A.

Published Aug 6, 2026, 4:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 7, 2026, 7:42 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$ILMN

Neutral

medium confidence

Mentioned

$ILMN

Relevance

8/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ILMNNeutralLow

Why it matters

A director’s large open-market sale can influence short-term sentiment and options positioning, but the filing does not include any new company-specific performance, guidance, or regulatory developments.

Market read

Traders may monitor for follow-on selling or interpret the transaction as a sentiment signal, but there is no new fundamental catalyst in the text.

What to watch

Indirect holdings and multi-trade execution can reflect pre-planned personal tax or estate liquidity needs rather than a view on ILMN fundamentals.

Relevance 8/10Novelty 5/10Timing: filed Aug 6, covering sales on Aug 4-5

Background

This is an SEC Form 4 insider transaction disclosure for Illumina, Inc. (ILMN).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ILMNNeutralMedium confidence

Context

Illumina director Keith A. Meister sold $148.2M of ILMN via 14 open-market trades at $196.74 to $203.28, indirect holdings.

Expected impact

Likely limited, short-lived negative drift around insider-selling headlines; no direct guidance or business update is provided.

Evidence & confidence

The filing is a Form 4 insider transaction with no 10b5-1 plan and a sizable notional, which can affect sentiment. However, the article contains no new operational, financial, or regulatory facts that would reprice fundamentals.

Market effects

Sector

Could marginally affect sentiment toward genomics tools/diagnostics peers if traders extrapolate insider risk, but no sector-wide catalyst is disclosed.

Regional

Primarily US large-cap sentiment; no cross-region linkage is provided.

Global

No global macro or international transaction details are included.

Counterpoint

What could challenge this read

The sale may be routine liquidity or diversification, and the absence of a stated 10b5-1 plan does not necessarily imply negative company outlook.

Key entities

issuer
Illumina, Inc.
Subject of the Form 4 insider sale; director Keith A. Meister reduced indirect holdings.
insider
Meister Keith A.
Director who sold 741,127 shares across 14 trades for about $148.16M.

Read at source ← All news

SEP 18

$ILMNHighAI 8/10

Illumina Q2FY26 Results: Revenue up 9.5% to $1.16 billion

Illumina reported Q2 2026 revenue of $1.16B, up 9.5% YoY, driven by NovaSeq X demand and clinical consumables growth. Non-GAAP EPS rose 10% to $1.31. The company raised full-year guidance, projecting revenue of $4.60B-$4.64B and EPS of $5.30-$5.40. Management cited strong instrument placements and cost management despite rising expenses. Illumina repurchased 0.9M shares and holds $1.17B in cash. The stock has returned 13.26% annually over 20 years, outperforming the market by 3.84%.

scanx.trade3 min

SEP 18

$ILMNHighAI 8/10

Illumina Reports Q2 2026 Results: Full Earnings Call Transcript - Illumina (NASDAQ:ILMN)

Illumina (ILMN) reported Q2 2026 revenue growth of 9.5% YoY and EPS growth of 10%, driven by strong demand for NovaSeq X. The company raised its 2026 guidance, expecting full-year organic revenue growth over 5% and mid-teens growth in clinical consumables. Strategic initiatives include expanding multi-omics capabilities and strengthening the BioInsight platform. Management emphasized cost management and confidence in long-term targets.

benzinga.com3 min

SEP 17

$ILMNMedAI 9/10

There's a biotech stock on Josh Brown's list that's ignoring the market noise and pushing higher

Illumina (ILMN) stock has risen 160% from its October 2025 low, defying broader market trends. The genomics company reported Q2 revenue of $1.16B, up 9.5% YoY, and raised full-year guidance. The stock is up 74.5% YTD and will be added to the S&P 500. Analysts note its strong technical performance and relative strength.

cnbc.com3 min

SEP 17

$BLSMHighAI 8/10

Biotech Stocks At 52-Week Highs - BLSM +18% On Positive Trial Data, ADPT, ILMN, CBLL, NEOG

Biotech stocks BLSM, NEOG, ILMN, CBLL, and ADPT hit 52-week highs. BLSM rose 18% on positive trial data, NEOG grew 2% with Q4 revenue of $225M, ILMN reached $236 on 9.5% Q2 growth, CBLL hit $25.63 with Q2 revenue up 33%, and ADPT climbed 3% with full-year revenue forecast between $268M-$278M.

rttnews.com3 min

SEP 16

$BELow

Three Stocks Are Joining the S&P 500. Will They Actually Improve VOO’s Returns?

Vanguard S&P 500 ETF (VOO) will add Bloom Energy (BE), Illumina (ILMN), and another company, while removing Molson Coors (TAP), The Trade Desk (TTD), and Builders FirstSource (BLDR). BE's product revenue surged 215% due to AI demand, and ILMN raised EPS guidance. The changes have minimal impact on VOO's returns, as the fund is heavily concentrated in megacap stocks.

yahoo.com3 min

SEP 15

$ILMNHigh

Illumina Stock Climbs As Analyst Upgrades Meet S&P 500 Boost

Illumina Inc. (ILMN) shares rose 7.15% on September 15, 2026, after UBS upgraded it to Buy with a $260 price target, and Argus raised its target to $235. The company's Q2 revenue was $1.16B, with EBITDA of $354M. Illumina is also being added to the S&P 500, effective September 21, 2026, which may drive further demand. The stock trades at a P/E ratio of 38 and P/S ratio of 6.9, reflecting its growth prospects. Analysts cite revenue reacceleration, margin expansion, and clinical demand as key driv

stockstotrade.com2 min